Case report shows complete remission of chronic disease in a 62-year-old woman, suggesting abrocitinib may be effective for systemic treatments.
Erosive lichen planus is a rare, chronic, immune-mediated inflammatory disease that can lead to significant morbidity. Erosive lichen planus is often resistant to therapies, and spontaneous remission is uncommon. We report the case of a 62-year-old woman with severe and refractory erosive lichen planus involving the oral, genital, and esophageal mucosa, who failed multiple systemic treatments. Initiation of abrocitinib, a selective Janus Kinase 1 inhibitor, led to complete and sustained clinical remission.
No takes yet. Share an insight, caveat, or question.
Hladky et al. (2025) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: